Eyepoint Pharmaceuticals Inc
$ 15.07
0.94%
20 Apr - close price
- Market Cap 1,245,639,000 USD
- Current Price $ 15.07
- High / Low $ 15.33 / 14.79
- Stock P/E N/A
- Book Value 0.40
- EPS -3.17
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.39 %
- ROE -0.72 %
- 52 Week High 19.11
- 52 Week Low 5.30
About
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$37.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-05 | 2025-08-07 | 2025-05-06 | 2025-03-05 | 2024-11-08 | 2024-08-07 | 2024-05-08 | 2024-03-07 | 2023-11-01 | 2023-08-02 | 2023-05-03 |
| Reported EPS | -0.81 | -0.85 | -0.85 | -0.65 | -0.64 | -0.54 | -0.58 | -0.55 | -0.33 | -0.33 | -0.61 | -0.56 |
| Estimated EPS | -0.7477 | -0.77 | -0.81 | -0.41 | -0.4765 | -0.55 | -0.52 | -0.42 | -0.49 | -0.51 | 0.6 | -0.68 |
| Surprise | -0.0623 | -0.08 | -0.04 | -0.24 | -0.1635 | 0.01 | -0.06 | -0.13 | 0.16 | 0.18 | -1.21 | 0.12 |
| Surprise Percentage | -8.3322% | -10.3896% | -4.9383% | -58.5366% | -34.3127% | 1.8182% | -11.5385% | -30.9524% | 32.6531% | 35.2941% | -201.6667% | 17.6471% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.79 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EYPT
2026-04-17 07:38:41
EyePoint, Inc. announced it granted non-statutory stock options to 14 new employees as inducement awards under NASDAQ Listing Rule 5635(c)(4). These options, totaling 362,500 shares, were granted on April 15, 2026, with an exercise price of $14.63 per share and a four-year vesting schedule. The grants were approved by the Compensation Committee to incentivize new hires.
2026-04-17 04:09:10
EyePoint, Inc. announced the granting of non-statutory stock options to fourteen new employees as inducement awards, in accordance with NASDAQ Listing Rule 5635(c)(4). These options cover 362,500 shares of EyePoint common stock, with an exercise price of $14.63 per share, vesting over four years. The company is focused on developing and commercializing therapeutics for serious retinal diseases, with its lead product candidate, DURAVYU, currently in Phase 3 trials.
2026-04-16 20:09:10
EyePoint (Nasdaq: EYPT) has granted non-statutory inducement stock options for an aggregate of 362,500 shares to fourteen new employees, effective April 15, 2026. The options have an exercise price of $14.63, a 10-year term, and vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments. These grants were approved by the Compensation Committee in accordance with NASDAQ Listing Rule 5635(c)(4).
2026-04-15 15:40:22
JPMorgan Chase & Co. significantly reduced its stake in Eyepoint Pharmaceuticals (NASDAQ:EYPT) by 87.8% in the third quarter, selling 217,150 shares and retaining 30,262 shares valued at $431,000. Despite this sell-off, Wall Street analysts largely maintain a bullish stance with an average "Buy" rating and a consensus price target of $32.20. The company's fundamentals currently appear weak, having reported a quarterly EPS miss of ($0.81), negative net margin, and negative return on equity, with shares trading around $14.34.
2026-04-14 03:39:46
EyePoint, Inc. (EYPT) filed an 8-K detailing its updated investor presentation for DURAVYU, a sustained-release tyrosine kinase inhibitor for retinal disease. The presentation outlines Phase 3 programs for wet age-related macular degeneration (AMD) and diabetic macular edema (DME), with topline wet AMD data expected in mid-2026. The company also reported approximately $220 million in cash and investments as of March 31, 2026, which is projected to fund operations into the fourth quarter of 2027.
2026-04-14 02:39:59
EyePoint Pharmaceuticals provided an update on its DURAVYU Phase 3 trials for wet AMD and DME, confirming full enrollment for wet AMD trials with data expected mid-2026, and DME trial enrollment completion by Q3 2026. The company also reported a substantial cash runway into late 2027 and is advancing manufacturing scale-up for DURAVYU, positioning it for the large retinal anti-VEGF market. EyePoint (EYPT) currently holds a "Neutral" rating from Spark's AI Analyst, despite positive pipeline developments, due to financial performance concerns.
